Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
National Comprehensive Cancer Network
Celgene Corporation
Genentech, Inc.
Information provided by (Responsible Party):
University of Tennessee Cancer Institute
ClinicalTrials.gov Identifier:
NCT00777673
First received: October 20, 2008
Last updated: January 3, 2013
Last verified: January 2013

October 20, 2008
January 3, 2013
October 2008
January 2013   (final data collection date for primary outcome measure)
Pathological complete response (pCR) in the breast [ Time Frame: No interim efficacy analysis is planned. It is anticipated that the definitive analysis would be performed approximately 3 years after initiation of accrual (2 years to accrue 60 patients plus one additional year of follow up) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00777673 on ClinicalTrials.gov Archive Site
Rate of near pCR/pCR of breast, axillary Ns & non axillary SNs cRR with nab-paclitaxel + carbo with bev cRR post neoadj Tx Rate of breast conserving surgery Safety & tolerability Disease free survival Identify gene(s) that may predict pCR to Tx [ Time Frame: Approximately 3 years from study initiation ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer

The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast). Bevacizumab is a drug that works by blocking new blood vessel formation by the tumor cells. Giving chemotherapy and bevacizumab before surgery may allow for lesser amount of breast tissue to be removed. To be able to predict in the future which patients are more likely to get pCR to this drug combination, specialized tests on tumor tissue will be performed.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim

Eligible patients will receive:

  • nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.
  • Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.
  • Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.

After completion of the above regimen, patients will receive:

  • Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.
  • Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.
  • Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.

Patients will then proceed with:

- Surgery including axillary staging

A minimum of 4 weeks post operatively, patient will receive:

- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses.

Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
October 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must be female and ≥ 18 years of age.
  • ECOG performance status 0 or 1
  • Diagnosis of invasive adenocarcinoma of the breast must be made by a core needle biopsy. ER, PR and HER2 must be available on the initial diagnostic biopsy and must be negative. HER2 negativity is defined as 0 or 1+ staining on IHC or documented non amplification by FISH. Patients with 2+ staining on IHC must be non amplified by FISH. Patients with tumors determined to be 3+ on IHC or amplified for HER2 by FISH are ineligible.
  • Primary breast tumor must be ≥ 2cm and meet RECIST criteria for palpable measurable disease. Two synchronous tumors in the same breast are allowed, but one of them must be ≥ 2 cm and clinically palpable at baseline.
  • Patients must agree to submission of two additional core biopsy specimens for correlative studies.
  • A baseline cardiac ejection fraction ≥ lower limit of normal (LLN) for the imaging facility must be obtained within 21 days of study entry.
  • EKG with no acute or significant abnormalities, obtained within 21 days of study entry.
  • Adequate hematologic, renal and hepatic function (ANC ≥ 1,500, platelet count ≥100,000, hemoglobin > 10, serum creatinine ≤ upper limit of nor (ULN) for the institution, total bilirubin ≤ 1.5 mg/dL, and AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2 x ULN) obtained within 21 days of study entry.
  • Urine protein/urine creatinine (UPC) ratio must be < 1.0. Patients discovered to have a UPC > 1.0 at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible.
  • Patients with reproductive potential must use an effective method of contraception to avoid pregnancy for the duration of the trial.
  • If female of child bearing potential, pregnancy test must be documented as negative.

Exclusion Criteria:

  • Patients with documented metastatic disease are ineligible.
  • Patients with tumors clinically staged as T4, including inflammatory cancer are ineligible.
  • Patients with ipsilateral cN2b or cN3 disease are ineligible. (cN1 or cN2a disease are eligible)
  • Patients who have had any prior chemotherapy, radiation therapy, hormonal or biologic therapy for the currently diagnosed breast cancer prior to study entry are ineligible.
  • Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. (Patients are eligible only if these medications are discontinued prior to randomization.)
  • Patients with any major surgery, open biopsy or significant traumatic injury within 28 days prior to study entry or anticipation of major surgery during the study other than their definitive breast surgery are ineligible.
  • Patients with surgical axillary staging prior to study entry are ineligible. FNA of clinically palpable nodes is permissible. Although not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes is permissible.
  • Patients must not have a significant history of cardiac disease (congestive heart failure New York Heart association (NYHA) Grade II or greater, uncontrolled hypertension {defined as BP > 150/90 on antihypertensive therapy. Patients with hypertension that is well controlled on medication are eligible.} unstable angina, myocardial infarction or ventricular arrhythmias requiring medications within 12 months prior to study entry. Prior history of hypertensive crisis or hypertensive encephalopathy.
  • Patients with a prior history of TIA, CVA or other arterial thrombotic events prior to study entry are ineligible.
  • Patients with significant vascular disease (e.g., aortic aneurysm, aortic dissection) or symptomatic peripheral vascular disease are ineligible.
  • Patients with any significant non traumatic bleeding within 6 months prior to study entry are ineligible.
  • Patients with serious or non healing wound, skin ulcers or incompletely healed bone fractures are ineligible.
  • Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment are ineligible.
  • Patient with known bleeding diathesis or coagulopathy are ineligible. Patients on a stable dose of warfarin with a therapeutic INR between 2 and 3 are eligible.
  • Patients with sensory or motor neuropathy ≥ grade 2 (NCI Common toxicity criteria adverse events version 3.0) are ineligible.
  • No prior malignancy is allowed with the exception of treated basal or squamous cell carcinomas of the skin, cervical cancer in situ, or any other cancer provided that the patient has been disease free for ≥ 5 years.
  • Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up.
  • Patients with known infection with HIV, HBV or HCV are ineligible.
  • Patients with psychosocial conditions that preclude medical follow up and compliance with the treatment protocol are ineligible.
  • Patients with known hypersensitivity to any of the study drugs are ineligible.
  • Administration of any investigational agents within 30 days before study entry.
  • Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00777673
BRE 01-08
Yes
University of Tennessee Cancer Institute
University of Tennessee Cancer Institute
  • National Comprehensive Cancer Network
  • Celgene Corporation
  • Genentech, Inc.
Principal Investigator: Jasgit C. Sachdev, MD University of Tennessee Cancer Institute
University of Tennessee Cancer Institute
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP